艾迪注射液并肝动脉介入治疗原发性肝癌92例临床观察

Clinical efficacy of aidi injection combined with transcatheter arterial chemoembolization in 92 patients with primary hepatic carcinoma

目的：评价中药艾迪注射液合并肝动脉介入治疗法治疗肝癌的疗效。方法：92例原发性肝癌患者随机分为试验组和对照组，每组各46例。试验组采用艾迪注射液60mL＋0．9％氯化钠溶液500mL静脉点滴，d1～d21；静滴同时进行肝动脉介入治疗，药物为羟基喜树碱（HCPT）10mg，氟尿嘧啶（5-FU）500mg，碘化油10mL，按Seldinger＇s技术要求，将药物注入肝脏肿瘤供养血管并行栓塞，28d为1周期。对照组46例单用肝动脉介入治疗方案，同试验组，2个周期后评价。结果：试验组和对照组的有效率分别为80．4％和63．4％，中位生存期8．34月和8．21月，平均生存期12．56月和9．24月，半年生存率89．1％和84．8％，1年生存率63．4％和47．8％，2年生存率28．3％和17．4％。全组初治者半年生存率83．1％，1年生存率46．2％，2年生存率18．5％，复治者则分别为96．2％，77．8％，33．3％。AFP疗后下降者试验组25例有效率为69．4％，对照组18例，有效率为54．5％。结论：艾迪注射液能提高肝动脉介入治疗率，改善生存质量，延长生存期，多次治疗能提高疗效。

Objective：To evaluate the efficacy of aidi injection combined with transcatheter arterial chemo- embolization in patients with primary hepatic carcinoma. Methods： Patients with primary hepatic carcinoma （n = 92） were randomly divided into two groups. Patients （n = 46） were treated with intravenous aidi injection （60 mL in 500 mL 0.9% NaCl） for 21 days （d 1 - 21 ） , and combined with transcatheter arterial chemoembolization （HCPT 10 mg, 5-Fu 500 mg and iodinate oil 10 mL） for 28 days according to seldinger＇s technique. The control patients （n = 46） were treated with transcatheter arterial chemoembolization alone. After 2 circles of 28-day treatment, the therapeutic effects were evaluated. Reauits： In aidi and control groups, the effective rates were 80.4% and 63.0% ; the median survival time was 8.34 and 8.21 months; the mean survival time was 12.56 and 9.24 months; the half-a-year survival rate was 89.1% and 84.8% ; one-year survival rate was 63.4% and 47.8% ; and two-year survival rate was 28.3% and 17.4% , respectively. For the initial patients in the two groups, the overall half-a-year survival rate was 83.1% , one-year survival rate was 46.2% , and two-year survival rate was 18.5% ; for the retreated patients, the corresponding rates were 96.2% , 77.8% and 33.3%. The AFP decline rate was 69.4% in 25 patients of aidi group, and was 54.5% in 18 patients of control group. Conclusion： Aidi injection can enhance the effect of transcatheter arterial chemoembolization, improve the quality of the patients＇ life and pro- long the survival time in patients with primary hepatic carcinoma; the efficacy can be improved after repeated treatment.